Blood Flow-limited Models
Blood Flow-limited Models - Related Videos
00:57
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
0 Views •
2025
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
10:25
Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
0 Views •
Cited by 9 •
2016
Platelet transfusion and hemostasis was modeled using blood reconstitution and microfluidic flow chambers to investigate the function of blood banking platelets. The data demonstrate the consequences of platelet storage lesion on hemostasis, in vitro.
03:38
Developing a Cerebral Blood Flow Atlas for Blood Flow Mapping
0 Views •
2025
Source: Tan, Z., et al., Construction and Application of Cerebral Functional Region-Based Cerebral Blood Flow Atlas Using Magnetic Resonance Imaging-Arterial Spin Labeling. J. Vis. Exp. (2024).This video demonstrates the method to construct a cerebral blood flow atlas by integrating magnetic resonance imaging or MRI-arterial spin labeling data with segmented brain regions, visualizing blood flow patterns, and quantifying flow levels across functional areas.
02:31
Diffuse Correlation Spectroscopy to Assess Cerebral Blood Flow in a Mouse Model
0 Views •
2025
In this video, we demonstrate the diffuse correlation spectroscopy technique to measure cerebral blood flow in a mouse model of mild traumatic brain injury.
07:46
Setting Limits on Supersymmetry Using Simplified Models
0 Views •
Cited by 6 •
2013
This paper demonstrates a protocol for recasting experimental simplified model limits into conservative and aggressive limits on an arbitrary new physics model. Publicly available LHC experimental results can be recast in this manner into limits on almost any new physics model with a supersymmetry-like signature.
FAQs
When membrane transport and tissue diffusion do not dominate, the amount of drug delivered to an organ per unit time becomes a major determinant of its exposure. Higher delivery can change how quickly drug reaches the tissue, whereas reduced perfusion can slow delivery. The model therefore links concentration–time behavior to organ blood flow rather than treating exposure as independent of circulation.
Drug–tissue partitioning determines how drug concentrations relate between an organ and the blood supplying it. Incorporating this property allows the model to represent differences in tissue exposure even when organs receive drug through the circulation. Consequently, tissues with different partitioning behavior may be predicted to have different concentrations, supporting comparisons of exposure across the liver, kidney, brain, and muscle.
Blood flow-limited models assign the dominant limitation to delivery through the circulation, while diffusion- or membrane-limited approaches emphasize movement across tissue barriers or membranes. This distinction changes which variables primarily determine predicted exposure. For the blood flow-limited approach, organ perfusion is central; for the related approaches, transport or diffusion properties would exert greater control over distribution.
Systemic clearance helps determine how quickly drug is removed from the body and therefore influences the overall concentration–time profile. In combination with organ blood flow and drug–tissue partitioning, it helps connect circulating concentrations with tissue exposure. Including clearance is important when evaluating how changes in organ function may alter drug disposition and predicted clinical concentrations.
A modeler considers organ blood flow, drug–tissue partitioning, and systemic clearance together to predict how concentrations change over time. The resulting profiles can be examined for differences in circulating and tissue exposure across organs. This supports interpretation of distribution behavior and helps relate pharmacokinetic patterns to the delivery and removal of drug within the body.
They are useful when clinicians or pharmacologists need to anticipate how distribution and clearance may influence drug exposure. By representing major organs and their blood delivery, the models support dose selection and interpretation of differences in concentration–time behavior. They also provide a framework for considering variability associated with altered circulation or changes in organ function.
Changes in circulation can modify the rate at which drug reaches tissues, while altered organ function can affect disposition and systemic clearance. The model makes these influences visible in predicted tissue exposure and concentration–time profiles. This application is particularly relevant when evaluating how disease-related changes in blood delivery or organ performance could modify clinical pharmacokinetics.